First nasal monoclonal antibody COVID-19 treatment shows potential
COVID-19 and multiple sclerosis patients experienced reduced inflammation when given the first nasal monoclonal antibody in a pilot trial.
List view / Grid view
COVID-19 and multiple sclerosis patients experienced reduced inflammation when given the first nasal monoclonal antibody in a pilot trial.
New pre-clinical research demonstrates the potential of gastric autoinjectors to deliver mRNA in sufficient quantities for vaccination.
Scientists found digital pill systems to be a 98 percent accurate intervention to help men adhere to pre-exposure prophylaxis (PrEP) regimens.
The novel, non-invasive test detects a rejection signature within mRNA isolated from urine and could, with further development, be used instead of biopsies to identify transplant rejection.
According to a new study, vaccines delivered via skin scarification were better at inducing T cell activity in pre-clinical animal models.
A new slow-release formulation and delivery system for the oral contraceptive pill has shown success in pre-clinical trials and could be taken once a month.
A new study undertaken to better understand the economic impact of brand-brand competition finds this does not lower drug prices.
A research group has designed a pills-on-a-coil system to administer drugs without having to take pills.
Researchers have developed a highly sensitive, mechanical needle that targets tissue reliably and precisely for the delivery of therapeutics...
A collaboration between Brigham and Women's Hospital and Vanderbilt University Medical Center looks to advance the application of AI in health...
A compressed injection pill could be the future alternative to injections of insulin delivery for patients with type 2 diabetes...
A study has found that when compared with other drugs, canagliflozin may not be associated with fractures in patients with diabetes...
Lorcaserin decreased risk for diabetes, induced diabetes remission and reduced risk of diabetes complications in obese and overweight patients...
Higher daily doses of rifampin, a cornerstone of tuberculosis treatment, were shown to kill more TB bacteria in sputum cultures without increasing the adverse effects of treatment, according to a recent randomised controlled trial.
A tricked-out cholera vaccine starts protecting against the deadly disease within a day, experiments in rabbits suggest.